Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

Kumamoto University

Status: Completed

Conditions: Age-related Macular Degeneration

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT01032109

PCBK610

Details and patient eligibility

About

The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.

Enrollment: 45 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• choroidal neovascularization caused by age-related macula degeneration
• no previous treatment
• a follow-up at least 12 months
• a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart

Exclusion criteria

• choroidal neovascularization caused by other eye diseases
• ocular surgery within the past 3 mouths
• history of uveitis
• intraocular pressure higher than 25 mmHg, or glaucoma
• history of systemic or ocular thromboembolic events.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

45 participants in 1 patient group

Bevacizumab

Experimental group

Treatment:

Drug: Bevacizumab